Patisiran (Onpattro)

Covered only for the FDA‑approved indication: treatment of the polyneuropathy of hereditary transthyretin‑mediated (hATTR) amyloidosis in adults (no off‑label uses); approval is for 12 months with dosing 0.3 mg/kg IV every 3 weeks (maximum 30 mg). Key requirements: genetic confirmation of hATTR, documented symptomatic peripheral neuropathy, age ≥18, prior or current trial of a gabapentin‑type agent or a tricyclic antidepressant, prescription or consultation by a neurologist/geneticist/amyloidosis specialist, and supporting documentation.

"Documentation of age demonstrating the patient is at least 18 years of age."

Sign up to see full coverage criteria, indications, and limitations.